Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:47:24.499Z.
Calculation as of: 2026-10-06T20:47:24.499Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$557.32M
EV/Sales Ratio
29.82x
TTM Avg
14.16x
3Y Avg
5.32x
5Y Avg
4.09x
Market Cap
$571.13M
EV/Sales Ratio
0.99x
TTM Avg
2.91x
3Y Avg
806.84x
5Y Avg
1105.61x
Market Cap
$548.51M
EV/Sales Ratio
2.22x
TTM Avg
5.65x
3Y Avg
62.35x
5Y Avg
62.35x
Market Cap
$578.40M
EV/Sales Ratio
9.96x
TTM Avg
11.75x
3Y Avg
7.27x
5Y Avg
5.37x
Market Cap
$538.01M
EV/Sales Ratio
570.49x
TTM Avg
273.93x
3Y Avg
336.09x
5Y Avg
336.09x
Market Cap
$583.31M
EV/Sales Ratio
2.60x
TTM Avg
2.20x
3Y Avg
3.12x
5Y Avg
5.45x
Market Cap
$584.48M
EV/Sales Ratio
1.75x
TTM Avg
1.86x
3Y Avg
1.97x
5Y Avg
1.94x
Market Cap
$533.04M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | 29.82x | 14.16x | 5.32x | 4.09x |
| CorMedix Inc. (CRMD)vs › | $571.13M | 0.99x | 2.91x | 806.84x | 1105.61x |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | 2.22x | 5.65x | 62.35x | 62.35x |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | 9.96x | 11.75x | 7.27x | 5.37x |
| ProKidney Corp. (PROK)vs › | $538.01M | 570.49x | 273.93x | 336.09x | 336.09x |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | 2.60x | 2.20x | 3.12x | 5.45x |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | 1.75x | 1.86x | 1.97x | 1.94x |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 5.10x | 4.75x | 15.43x | 15.84x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
